retatrutide phase 2 trial results Lilly orforglipron oral GLP-1 3 weight loss Phase 2 Trial of Retatrutide

Take our 5-minute clinical assessment The SELECT trial enrolled participants who were 84% white

About Mazdutide Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of mazdutide, a dual GCG /GLP-1 receptor agonist, in China

Investigators are also studying its effects on hepatic fat (MASLD/MASH), cardiovascular risk markers, and obstructive sleep apnea areas where appetite suppression alone cannot fully explain the observed improvements

Published in The New England Journal of Medicine in May 2025, this landmark study provides definitive evidence about how these two medications compare

29%), and both face challenges

How Long Should Subjects Remain on Maintenance Retatrutide Dosing